Pharma

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Most Viewed Abstracts



Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Wyeth Pharmaceuticals, a division of Wyeth, announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for the company’s pneumococcal conjugate vaccine, Prevenar 13*. The CHMP recommends approval of Prevenar 13 for active immunization of children aged 6 weeks to 5 years for the prevention of invasive pneumococcal disease, as well as pneumonia and otitis media caused by 13 pneumococcal serotypes.

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address